CLDN34: A Potential Drug Target and Biomarker (G100288814)

Target Name: CLDN34

NCBI ID: G100288814

CLDN34

CLDN34: A Potential Drug Target and Biomarker

CLDN34 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. CLDN34 is a highly conserved gene that is expressed in most tissues and cells in the body, but it is primarily expressed in the endothelial cells, which are responsible for maintaining blood flow and oxygenation of tissues.

The discovery of CLDN34 as a potential drug target and biomarker comes from a team of researchers at the University of California, San Diego, led by Dr. Qin Liu. The researchers identified that CLDN34 was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. They also found that CLDN34 was downregulated in these cancer cells compared to their corresponding non-cancerous cell types.

Furthermore, the researchers found that CLDN34 was associated with the development and progression of cancer. They observed that higher expression of CLDN34 was associated with a more aggressive and deadly form of cancer. Additionally, the researchers found that CLDN34 was overexpressed in various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

These findings suggest that CLDN34 may be a promising drug target and biomarker for various diseases. The researchers are currently conducting further studies to determine the effectiveness of targeting CLDN34 in cancer and neurodegenerative diseases.

CLDN34 as a drug target has the potential to treat various diseases, including cancer and neurodegenerative disorders. For example, targeting CLDN34 in cancer may be effective in slowing the growth and progression of cancer cells. The researchers are also exploring the potential of targeting CLDN34 in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Targeting CLDN34 may also have potential implications for treating other diseases, such as cardiovascular diseases and respiratory disorders. The researchers are currently conducting further studies to determine the effectiveness of targeting CLDN34 in these diseases.

In conclusion, CLDN34 is a promising drug target and biomarker for various diseases. The research conducted by the team at the University of California, San Diego has identified the potential for targeting CLDN34 in cancer and neurodegenerative diseases. Further studies are needed to determine the effectiveness of targeting CLDN34 in these diseases and to explore the potential implications for treating other diseases.

Protein Name: Claudin 34

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets